From the qrtly.
BARD1 commenced its own in-house ELISA development using SubB2M for monitoring of other cancers including prostate and pancreatic cancer. Following a successful ethics application, samples will be obtained from the VCB in the first quarter of CY2021, with assay development to follow shortly thereafter. The SubB2M technology could enable the development and commercialization of fast-to-market, next-generation tests with the potential to revolutionise cancer detection and monitoring.
Chart Thread, page-175
-
- There are more pages in this discussion • 1,318 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
-0.015(3.13%) |
Mkt cap ! $51.85M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.0¢ | 46.0¢ | $95.71K | 205.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.20pm 11/10/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |